Recent studies have focused on hyperuricemia as a modulator for metabolic syndrome. Hyperuricemia has reported in many studies as a causal marker in a higher prevalence of metabolic syndrome. In fact, insulin resistance, dyslipidemia, obesity and hypertension, each of these variables of metabolic syndrome gets influenced by the serum uric acid level. High level of uric acid has been associated with metabolic syndrome, type 2 diabetes and cardiovascular diseases. Hyperuricemia has attributed to hyperinsulinemia in metabolic syndrome and decreased excretion of uric acid causing endothelial dysfunction in kidney leads to renal disease and cardiovascular disorders. This review focus on the role of uric acid in the development of metabolic syndrome and on the possible pathophysiology.

**Key Words:** Hyperuricemia, Uric acid, Metabolic syndrome, Hypertension, Obesity

**INTRODUCTION**

Uric acid is an end product of purine metabolism in human and higher primates. Human lost uricase gene due to mutation occurred about 15 million years ago [1] and hence the level of uric acid in humans are much higher than other species. The uric acid is formed in the liver by the breakdown of nucleic acid and proteins. When the level of uric acid increases in blood beyond allowable level the condition is called as hyperuricemia. The uric acid level is higher in men compared to women which clearly show a link of uricosuric effect of estrogen [2].

Johnson et al. suggested the role of uric acid as an antioxidant, the increased level of uric acid has shown advantageous effects [3] on compensatory pathway in cardiovascular disease in response to the stress conditions [4]. Uric acid has detrimental effect in adipocytes and vascular smooth muscle cells [5,6] which clearly shows its proinflammatory nature. Hyperuricemia also leads to endothelial dysfunction by the impairment of nitric acid generation [7]. Oliveira et al. suggested that acute elevation of uric acid has protective effect while chronic elevation of uric acid exacerbates the risk of disease [8].

The association of hyperuricemia and the prediction for the development of metabolic syndrome has been seen [9-11]. Uric acid acts as an identifying factor for the high risk asymptomatic individuals in the prognosis of metabolic syndrome that leads to an improvement in the treatment for the upcoming cardiovascular events [12]. Until now the pathogenic role of uric acid in the development of the metabolic syndrome is not completely comprehended. Hence this review would provide an insight into the linked pathways between hyperuricemia and each component of metabolic syndrome.
HYPERURICEMIA AND INSULIN RESISTANCE
Insulin resistance is a condition in which a normal amount of insulin produces a subnormal biological response. It is one of the most important factors for uric acid regulation in the body. Studies have demonstrated the association between high serum uric acid and insulin resistance but the causal relation is less reviewed.
Facchini et al. discussed that insulin resistance is inversely proportional to the uric acid clearance from the kidney [13] and hence the level of uric acid gets accumulated in the kidney. Studies also revealed the positive correlation of hyperuricemia with elevated fasting insulin level [14]. The mechanism of insulin resistance induces hyperinsulinemia suggested by animal as well as human studies. Some of them conclude that insulin resistance promotes hyperinsulinemia, which may enhance renal urate reabsorption by the activation of urate-anion exchange URAT1 [17] and Na dependent anion cotransporter in renal proximal tubules [15,16]. It has been reported that insulin increases renal tubular sodium reabsorption [15,20] reduces the uric acid excretion which increases the serum uric acid level.
Carnethon et al. observed a follow-up study on increasing uric acid among non-diabetic individuals which had higher risk for developing hyperinsulinemia [18]. Another study on animal professed the lowering of uric acid by xanthine oxidase inhibitors which reduces insulin resistance in obese mice demonstrated by Baldwin et al. [19].
Johnson et al. proposed a mechanism through which fructose accumulates uric acid and induce insulin resistance. Increase in uric acid cause proinflammatory effect on adipocytes. As has been discussed earlier hyperuricemia leads to the endothelial dysfunction that impairs the bioavailability of nitric oxide, and lead to insulin resistance. While the systemic effect of uric acid on skeletal muscle impairs glucose uptake, further it leads to insulin resistance [7,21,22]. In addition to this insulin resistance may occur by alcohol intake, obesity and from various other reasons but the process of development of hyperuricemia and insulin resistance shares the convertible bidirectional causal effects.

HYPERURICEMIA AND HYPERTENSION
The most researchers have studied about uric acid as an inducible factor that helped to understand the pathogenesis of hypertension [23,33,36]. Hyperuricemia could be one of the culprits and it is well known as an independent risk factor for hypertension [23]. Kim et al. observed a significant positive correlation between hyperuricemia and the incidence of hypertension [24-26]. Yeh et al. suggested that plasma uric acid relates with diastolic blood pressure not the systolic hypertension [27]. The possible reason behind this is unknown.
Surprisingly the association of hyperuricemia and blood pressure diminished in the elderly patients [28-30]. The possible mechanism was that uric acid damages small renal vessels, which leads to an irreversible salt sensitive hypertension. The reason for not lowering uric acid by specific uric acid inhibitor in these subjects concludes that there must be some other pathophysiological mechanism of hypertension [31]. Dietary habits and specific foods (table sugar and high-fructose corn syrup) are also important factors in determining hyperuricemia induced hypertension. Nakagawa et al. observed the role of uric acid in fructose induced metabolic syndrome in rats. Animals fed with high fructose elevated the level of uric acid along with insulin, triglyceride, and blood pressure [32]. Mazzali et al. observed that when rats were fed with uricase inhibitor for developing hyperuricemia, few weeks after developing hyperuricemia these animals developed the hypertension too. A xanthine oxidase inhibitor or a uricosuric drug decreased blood pressure by reducing uric acid level in animals. It means that hypertension was developed due to vasoconstriction medicated by uric acid, with the reduction in the bioavailability of nitric oxide level and activation of the renal - angiotensin system [36].
Another mechanism published by Daniel et al. about the linking pathway of uric acid mediated hypertension suggests that purine rich meat or excessive fructose may result chronic hyperuricemia. Obese mother with preexisting hypertension or preeclampsia may pass the uric acid into infant circulation and it leads to intrauterine growth retardation and reduction in the nephron number. Further hyperuricemia develops in the new born babies may be due
to genetic and environmental factors. This chronic hyperuricemia stimulates renin angiotensin system and block the endothelial nitric oxide production, which contribute renal vasoconstriction and hypertension [33].

Until now there is no common agreement for the laboratory measurement of uric acid in the hypertensive subjects. Serum uric acid is not considered as a risk factor for hypertension by American Heart Association or the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure [34]. However, the guideline of European Society of Hypertension and Cardiology recommends serum uric acid as a laboratory measurement for hypertension [35].

HYPERURICEMIA AND OBESITY

Obesity is one of the pivotal causative of metabolic syndrome. It has been proven as a risk factor for hypertension, dyslipidemia and hyperuricemia. The positive association of obesity with increasing uric acid level has been found among several recent studies [48,49].

Waist circumference have been suggested as a measure of intra-abdominal fat mass, body mass index and waist-to-hip ratio is a simple indicator for the assessment of cardiovascular risk [37,38]. Indeed the prevalence of insulin resistance is increased in overweight/obese individuals [39,40]. The association of insulin resistance and obesity leads to the further development of the other factors of metabolic syndrome. Wajchenberg suggested that insulin resistance in adipose tissue leads to an inability to suppress the release of fatty acids from adipose tissue and thus it induced decrease in the clearance of triglyceride-rich lipoproteins [41]. Ultimately, abdominal obesity associated with insulin resistance and triglyceride may increase the uric acid level by the decreased insulin sensitivity (Fig. 1).

Matsuura et al. and Bonora et al. reported that obesity and central body fat distribution were associated with hyperuricemia [42,43]. Bedir et al. and Fruehwald-Schultes et al. conducted studies in the evaluation of relationship between leptin and the cluster of hyperuricemia in order to clarify the causative mechanisms associating obesity with hyperuricemia. They found that the serum uric acid concentration [44,45]. This study suggested that leptin could be a pathogenic factor responsible for hyperuricemia in obese patients. Chen et al. reported the relationship between hyperuricemia and waist circumference in hospital based cross-sectional study. The study showed that elevated waist circumference was significantly associated with hyperuricemia in both men and women [46]. In a study which was conducted in Portugal [47] for the association between waist circumference and uric acid, only high waist circumference remained significantly and positively associated with hyperuricemia.

Qian et al. explained [50] the pathophysiology of obesity that causes hyperuricemia: firstly obesity directly obstructs with urate protein synthesis and excretion [51], secondly obesity causes renal damage via glomerulus dysfunction [52] and thirdly, obesity leads to the dysfunction of the renin-angiotensin system, which would eventually result in the insignificant clearance of uric acid [53].

Studies regarding abdominal obesity done in lean and obese Japanese men showed that visceral adiposity measured by computerized tomography was a strong contributor to the elevated uric acid concentration possibly due to the reduction in its excretion [54,55]. In the Turkish Adult Risk Factor Study, abdominal obesity was the most important dete-
nant of uric acid concentration variability after the adjustment for 13 variables, including the use of alcohol, diuretics, high blood pressure, glucose regulation and gamma glutamyl transferase levels [56]. This study suggested that abdominal obesity is the main determinant of elevated plasma uric acid levels in the general population. A possible explanation would be that hyperinsulinemia, due to insulin resistance and visceral adiposity, leads to an increased uric acid absorption in renal tubules [16]. Masuo et al. have noted that hyperuricemia predicts the development of obesity following weight gain and high blood pressure [9]. It is now widely believed that increasing prevalence of obesity causes the hypertension [57]. Dietary habits are also responsible for the increasing prevalence of hyperuricemia. There has been a large increase of fructose intake in the developed world during the past 200 years which correlates with the increase in the prevalence of hypertension and obesity [58, 59].

Ryu et al. published a prospective study in Korean population, a cohort relating to hyperuricemia in middle aged Korean men. Subject with incident hyperuricemia were more likely to have high body mass index after 7 year follow up study [60]. It suggests that uric acid is associated with increase in the obesity.

HYPERURICEMIA AND DYSLIPIDEMIA

Dyslipidemia associated with insulin resistance is characterized by increased levels of VLDL, triglyceride, remnant particles and decreased levels of HDL-cholesterol. Epidemiological studies revealed the link between dyslipidemia and uric acid. Among men, uric acid concentration was positively correlated with waist circumference, blood pressure, and triglyceride. Uric acid concentration was strongly correlated with serum triglyceride. Conen et al. and Schechter showed the similar observation of correlation between triglyceride and hyperuricemia [61, 62].

Leyva et al. suggested the pathway of glycolysis in uric acid production. Phosphoribosylpyrophosphate (PPRP) is an important metabolite in this process. Its availability depends on ribose-5-phosphate (R-5-P), governed by glycolytic flux. Disturbances in the intermediates like R-5-P, PPRP, diminish the activity of GA3PDH (glyceraldehyde-3-phosphate dehydrogenase), which is regulated by insulin. Accumulation of glycerol-3-phosphate leads to an increase in serum triglyceride concentrations. The defects in GA3PDH and a loss of its responsiveness to insulin by causing the accumulation of glycolytic intermediates could explain the assortment among insulin resistance, hyperuricemia, and hypertriglyceridemia [63]. Chen et al. showed that serum uric acid level was negatively correlated with HDL-C level, but this association was not evident among women. This finding was consistent with Rho et al. [64, 65].

During triglycerides synthesis there would be a greater need for NADPH [66] and the synthesis of fatty acids in the liver which is associated with the de novo synthesis of purine, thus hastening uric acid production [42]. Tsouli et al. & Lin et al. suggested genetic and environmental factors to be responsible for this association [67] while some studies support the fact that dietary habit and alcohol consumption is the main reason for the increment of uric acid and triglyceride level [68, 69]. The free fatty acid produced by lipolysis is metabolized through beta oxidation with increased production of NADPH which further get metabolized to uric acid resulting in hyperuricemia [66, 70].

HYPERURICEMIA AND METABOLIC SYNDROME

The concept of the metabolic syndrome is existent since the last 80 years. In 1920, Kylin, a Swedish physician, first described a constellation of metabolic disturbance, which entailed the risk factors of cardiovascular disease, atherosclerotic cardiovascular disease and the clustering of hyperglycemia, hypertension and gout [71]. In 1988 Reaven [72] postulated that several risk factors-dyslipidemia, hyperglycemia, and hypertension commonly clustered together and recognized as the multiple risk factors for CVD. Some recent studies report that the prevalence of metabolic syndrome was high among the patients with gout [73, 74]. Sex related variations for metabolic syndrome prevalence has been seen by different studies. Uaratanawong et al. observed that the higher prevalence of metabolic syndrome was found in men with hyperuricemia [74]. Fig. 1 shows the close association of hyperuricemia with the individual component of metabolic syndrome.

Yang et al. in a follow up of Chinese population for 5.41
years stepwise increase in the incidence of metabolic syndrome across the tertiles of serum uric acid. Among women, this association was stronger than men. After adjusting variations in age, blood pressure, triglycerides, HDL-C, glucose, and waist circumference, females in the middle and upper tertiles of serum uric acid had significantly higher risk of developing metabolic syndrome when compared with subjects in the lowest tertile. Certain other studies showed positive relations between metabolic syndrome and uric acid [56,75-77].

A 1.6-fold higher risk for metabolic syndrome was noted in the individuals with serum uric acid levels in the highest compared with the lowest quartile [60]. Associations between serum uric acid level and metabolic syndrome have been reported in cross-sectional studies [56,75,78]. Choi et al. found that the prevalence of the metabolic syndrome was higher across the levels of serum uric acid in a nationally representative sample of NHANES III [75]. Sui et al. reported a follow up study in USA individuals for 5.7 years [79] where men with serum uric acid concentrations ≥6.5 mg/dl had a 1.60-fold increase in the risk of metabolic syndrome, as compared with those who had concentrations <5.5 mg/dl. The risk of metabolic syndrome was at least 2 folds higher in the women with serum uric acid concentrations ≥4.6 mg/dl. The study also suggests that hyperuricemia is a strong and independent predictor of incident metabolic syndrome in men and women [78]. Future predictor for CVD is one of the reasons to focus in these aspects [80,81] from the studies above mentioned risk populations. Although some researchers have debated on this issue whether uric acid should be an additional metabolic syndrome component [82,83] however, it has not been included in any of the diagnostic criteria like NCEP-ATP, IDF and WHO criteria.

The specific biologic mechanisms by which hyperuricemia increase the risk of developing metabolic syndrome remain ambiguous. Recently, an observation has linked to table sugar, high fructose corn syrup, and natural sources which provide fructose for the development of metabolic syndrome by predisposition of uric acid. The ingestion of fructose is strongly associated with obesity and insulin resistance epidemic [84]. Fructose-1-phosphate is formed by phosphorylation in fructose metabolism. Then enzyme aldolase B breaks fructose 1 phosphate into dihydroxyacetone phosphate (DHAP) and D glyceraldheyde. The reaction of aldolase is slow for the conversion of DHAP and glyceraldheyde. Thus, in the condition of high fructose intake, fructose -1-phosphate gets accumulated and further decreases the concentration of intracellular phosphate which limits the ATP formation. ADP or AMP resulting from such metabolism is catabolized, thus leading to hyperuricemia [85].

Hyperuricemia could play a role in the development of insulin resistance through urate-induced inhibition of endothelial nitric oxide [86]. A decrease in the endothelial nitric oxide may interrupt the normal functioning of insulin in the skeletal muscle [87]. Cook et al. observed the features of the metabolic syndrome in mice lacking endothelial nitric oxide synthase [88]. Further treatment with allopurinol can improve endothelial function in the patients with hyperuricemia [7,89]. In addition to this result Nakagawa et al. [32] found that lowering uric acid in fructose-fed rats improves the components of the metabolic syndrome, which clearly suggests that uric acid has a causal role in the metabolic syndrome. Sautin and Furukawa et al. observed inflammatory and oxidative changes in adipocytes after the treatment of uric acid; it suggested that they might be a process in causing metabolic syndrome [5,90]. Recent studies also [91-94] conclude that upper normal range of uric acid could be an indicating factor for the development of metabolic syndrome. Our group suggests that high quartile of uric acid within normal range may be surrogate markers of metabolic syndrome in general population. However this apprehension needs to be substantiated with ethnic-based cross sectional as well as follow-up study.

**CONCLUSION**

This review focuses on the association between hyperuricemia and the further development of individual variables of metabolic syndrome. The uric acid is one of the important markers to predict metabolic syndrome, diabetes and cardiovascular disease. Insulin resistance and uric acid interactions are crucial factor for determining the development of other metabolic syndrome components. The various defining criteria for the metabolic syndrome independently predict the cardiovascular disease and uric acid could also
include in the parameters of metabolic syndrome. Better definitions should be given so as not to confuse with different international criteria’s. Many studies clearly conclude that uric acid is not an innocent observer rather a culprit. Available study suggests that hyperuricemia appears to potentially contribute to obesity, hypertension, diabetes, renal and cardiovascular diseases. Hence, there should be an effective implementation in all aspects to reduce the adverse effects of uric acid in metabolic syndrome.

ACKNOWLEDGEMENTS

The research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A2044121).

REFERENCES

1. Johnson RJ, Lanaspa MA, Gauchera EA. Uric acid: A danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome and cardiorenal disease: evolutionary considerations. Semin Nephrol 2011;31:394-9.
2. Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J 1973;1:449-51.
3. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanae S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hyperpertension and cardiovasucular and renal disease? Hypertension 2003;41:1183-90.
4. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000;148:131-9.
5. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007;293:584-96.
6. Corry DB, Eslami P, Yamamoto K, Nyh MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008;26:269-75.
7. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabahkar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739-42.
8. de Oliveira EP, Burini RC. Higher plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr 2012;4:12-8.
9. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003;42:474-80.
10. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003;18:523-30.
11. Bickel C, Ruppprech HJ, Blankenberg S, Rippin G, Hafner G, Daunhauer A, Hofmann KP, Meyer J. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:12-7.
12. Yang T, Chu CH, Bai CH, You SL, Chou YC, Chou WY, Chien KL, Hwang LC, Su TC, Tseng CH, Sun CA. Uric acid level as a risk marker for metabolic syndrome: A Chinese cohort study. Atherosclerosis 2012;220:525-31.
13. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between Resistance to Insulin-Mediated Glucose Uptake, Urinary Uric Acid Clearance, and Plasma Uric Acid Concentration. JAMA 1991;266:3008-11.
14. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rhee JI, Lee WY, Kim SW, Ryu SH, Keum DG. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005;69:928-33.
15. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996;9:746-52.
16. Galvan AQ, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on serum uric acid excretion in humans. Am J Physiol 1995;268:1-5.
17. Doshi M, Takie Y, Saito H, Hosoyamada M. The increased protein level of URAT1 was observed in obesity/metabolic syndrome model mice. Nucleosides Nucleotides Nucleic Acids 2011;30:1290-4.
18. Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1997. Am J Epidemiol 2003;158:1058-67.
19. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011;60:1258-69.
20. Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in
healthy subjects. Clin Sci (Lond) 1997;92:51-8.
21. Baldus S, Koster R, Chumley P, Heitzer T, Rudolph V, Ostad MA, Warnholtz A, Staude HJ, Thuneke F, Koss K, Berger J, Meinertz T, Freeman BA, Münzel T. Oxyipurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med 2005;39:1184-90.
22. Roy D, Perreault M, Marette A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol 1998;274:692-9.
23. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 2006;73:1059-64.
24. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885-92.
25. Cigolini M, Targher G, Tonoli M, Manara F, Mugggeo M, De Sandre G. Hyperuricaemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women. Int J Obes Relat Metab Disord 1995;19:92-6.
26. Chu NF, Wang DJ, Liou SH, Shieh SM. Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan. Eur J Epidemiol 2000;16:13-7.
27. Yeh CJ, Pan WH, Jong YS, Kuo YY, Lo CH. Incidence of hypertension among adult males in Taiwan. J Formos Med Assoc 2001;100:668-75.
28. Kosugi T, Nakagawa T, Kamath D, Johnson RJ. Uric acid and hypertension: an age-related relationship? J Hum Hypertens 2009;23:75-6.
29. Lu Z, Dong B, Wu H, Chen T, Zhang Y, Wu J, Xiao H. Serum uric acid level in primary hypertension among Chinese nonagenarians/centenarians. J Hum Hypertens 2009;23:113-21.
30. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007;18:287-92.
31. Blacher J, Safar M. Specific aspects of high blood pressure in elderly. J Renin Angiotensin Aldosterone Syst 2002;3(Suppl 1):10-5.
32. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:625-31.
33. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
34. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002;106:388-91.
35. European Society of Hypertension-European Society of Cardiology. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension Guidelines committee. J Hypertens 2003;21:1011-53.
36. Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig D, Johnson RJ. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 2010;12:108-17.
37. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8.
38. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995;311:158-61.
39. Ferrannini E, Natali A, Bell P, Cavallo-Perin, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997;100:1166-73.
40. Abbas F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002;40:937-43.
41. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endo Rev 2000;21:697-738.
42. Matsuurua F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, Matsuzawa Y. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998;47:929-33.
43. Bonora E, Targher G, Zenere MB, Saggiani F, Caicciatori V, Tosi, F, Travia D, Zenti MG, Branzi P, Santi L, Mugggeo M. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 1996;20:975-80.
44. Bedir A, Tophas M, Tanyeri F, Alvar M, Arik N. Leptin might be a regulator of serum uric acid concentration in human. Jpn Heart J 2003;44:527-36.
45. Fruehwald-Schultes B, Peters A, Kern W, Beyer J, Pfutzner A. Serum leptin is associated with serum uric acid concentrations in humans. Metabolism 1999;48:677-80.
46. Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen...
JH, Chen LQ, Fang LZ. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B 2007;8:593-8.

47. Gonçalves JP, Oliveira A, Severo M, Santos AC, Lopes C. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine 2012;41:450-7.

48. Lin JD, Chiou WK, Chang HY, Liu FH, Weng HF. Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism 2007;56:751-6.

49. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 1996;45:699-706.

50. Zhang Q, Zhang C, Song X, Lin H, Zhang D, Meng W, Zhang Y, Zhu Z, Tang F, Liu L, Yang X, Xue F. A longitudinal cohort based association study between uric acid level and metabolic syndrome in Chinese Han urban male population. BMC Public Health 2012;12:419-26.

51. Marasini B, Massarotti M. What rheumatologists should know about gout and cardiovascular disease. J Rheumatol 2009;36:854-5.

52. Tuttle KR. Renal manifestations of the metabolic syndrome. Nephrol Dial Transplant 2005;20:861-4.

53. Indraratna PL, Williams KM, Graham GG, Day RO. Hyperuricemia, cardiovascular disease, and the metabolic syndrome. J Rheumatol 2009;36:2842-3.

54. Takahashi S, Yamamoto T, Tsutsui Z, Moriwaki Y, Yamakita J, Higashino K. Close correlation between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Metabolism 1997;46:1162-5.

55. Ishizaka N, Ishizaka Y, Ei-Ichi T, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005;25:1038-44.

56. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I, Yazici M, Koleş I. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006;19:1055-62.

57. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 2004;286:803-13.

58. Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005;63:133-57.

59. Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, Gersch MS, Benner S, Sánchez-Lozada LG. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007;86:899-906.

60. Ryu S, Chang Y, Zhang Y, Kim SG, Cho J, Son HJ, Shin H, Guallar E. A cohort study of hyperuricemia in middle-aged South Korean men. Am J Epidemiol 2012;175:133-43.

61. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, Burnier M. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004;4:1-9.

62. Schachter M. Uric acid and hypertension. Curr Pharm Des 2005;11:4139-43.

63. Leyva F, Wingrove CS, Godsland IF, Stevenson JC. The glycolytic pathway to coronary heart disease: a hypothesis. Metabolism 1998;47:657-62.

64. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Chung SH, Kim CG, Choe JY, Lee SW, Chung WT, Song GG. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005;20:1029-33.

65. de Oliveira EP, Manda RM, Torezan GA, Corrente JE, Burini RC. Dietary, anthropometric, and biochemical determinants of plasma high-density lipoprotein-cholesterol in free-living adults. Cholesterol 2011;2011:1-7.

66. Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur J Endocrinol 1998;138:63-9.

67. Tsouli SG, Liberopoulos EM, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated UA levels in MS: an active component or an innocent bystander? Metab Clin Exp 2006;55:1293-301.

68. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 1998;57:509-10.

69. Simao AN, Lozovoy MA, Dichi I. The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opin Ther Targets 2012;16:1175-87.

70. Vourinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and IR. J Clin Endocrinol Metab 1994;78:25-9.

71. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.

72. Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.

73. Lee WY, Park JS, Noh SY, Rhee EJ, Kim SW, Zimmet PZ. Prevalence of the metabolic syndrome among 40688 Korean metropolitan subjects. Diabetes Res Clin Pract 2004;65:143-9.

74. Unratanawong S, Suraamornkul S, Angkeaw S,
Uaratanawong R. Prevalence of hyperuricemia in Bangkok population. *Clin Rheumatol* 2011;30:887-93.

75. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med* 2007;120:442-7.

76. Reimann M, Schatte AE, Malan L, Huisman HW, Malan NT. Hyperuricemia is an independent factor for the metabolic syndrome in a sub-Saharan African population: a factor analysis. *Atherosclerosis* 2008;197:638-45.

77. Liu FW, Chang TY, Chen JD. Serum uric acid and metabolic syndrome in Taiwanese adults. *Metabolism* 2010;59:802-7.

78. Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. *Arch Med Res* 2006;37:883-9.

79. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric Acid and the development of metabolic syndrome in women and men. *Metabolism* 2008;57:845-52.

80. Niskanen LK, Laaksonen DE, Nyyssonen K, Alftan G, Lakka HM, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. *Arch Intern Med* 2004;164:1546-51.

81. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. *Stroke* 1998;29:635-9.

82. Liou TL, Lin MW, Hsiao LC, Tsai TT, Chan WL, Ho LT, Hwu CM. Is hyperuricemia another facet of the metabolic syndrome? *J Chin Med Assoc* 2006;69:104-9.

83. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin resistance syndrome. *Am J Clin Nutr* 2002;76:911-22.

84. Champe PC, Harvey RA. Biochemistry (Lippincott's illustrated reviews). (2nd ed.). Lippincott; Philadelphia. 1994. pp253-5.

85. Nakagawa T, Kang DH, Feig D, Sanchez-Lozada LG, Srinivas TR, Sautin Y, Ejaz AA, Segal M, Johnson RJ. Urate nephropathy: An ancient factor with recently found significance in renal and cardiovascular disease. *Kidney Int* 2006;69:1722-5.

87. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. *Nat Clin Pract Nephrol* 2005;1:80-6.

88. Cook S, Hugli O, Egli M, Vollenweider P, Burrelin R, Nicod P, Thorens B, Scherrer U. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. *Swiss Med Wkly* 2003;133:360-3.

89. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. *Am J Cardiol* 2004;94:932-5.

90. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. *J Clin Invest* 2004;114:1752-61.

91. Lee EY, Lee MY, Koh SB, Ahn SV, Chung CH. Serum uric acid levels within the normal range are independently associated with metabolic syndrome in the Korean Community-Based Cohort. *J Lifestyle Med* 2011;1:40-6.

92. Zhang ML, Gao YX, Wang X, Chang H, Huang GW. Serum uric acid and appropriate cutoff value for prediction of metabolic syndrome among Chinese adults. *J Clin Biochem Nutr* 2013;52:38-42.

93. Wang JY, Chen YL, Hsu CH, Tang SH, Wu CZ, Pei D. Predictive value of serum uric acid levels for the diagnosis of metabolic syndrome in adolescents. *J Pediatr* 2012;161:753-6.

94. Jin YL, Zhu T, Xu L, Zhang WS, Liu B, Jiang CQ, Yu H, Huang LM, Cheng KK, Thomas GN, Lam TH. Uric acid levels, even in the normal range, are associated with increased cardiovascular risk: The Guangzhou Biobank Cohort Study. *Int J Cardiol* 2013;168:2238-41.